Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...

AI, but he is on a mission to protect what makes art human. Chavous’s stance is reflected in his footprint as a founder, ...

Self-awareness—the ability to understand your emotional triggers, cognitive patterns and motivations—is the ultimate career ...

Neural and computational evidence reveals that real-world size is a temporally late, semantically grounded, and hierarchically stable dimension of object representation in both human brains and ...

This cloud will be an national talent architecture linking schools, universities, research institutions, start-ups, PSUs and ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, ...

AgingIN invites elder care leaders to the ReImagining Care Models conference for dynamic discussions on person-directed ...

High-profile incidents, different industries. An unmistakable pattern: GenAI hallucinations are enterprise liabilities, ...

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...